Edwards Receives CE Mark For PASCAL Transcatheter Tricuspid Valve Repair System
Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip.
You may also be interested in...
The company is sponsoring an early feasibility trial of the Intrepid transcatheter valve replacement system for patients with severe tricuspid regurgitation.
The company recorded $925m in revenue in the second quarter of 2020, exceeding the top end of its previous guidance, and expects to return to growth by the end of the year.
Edwards Lifesciences is paying Abbott Laboratories to settle disputes over patents on transcatheter mitral and tricuspid repair products.